Qian Wang

Qian Wang analyzed the evolution and genetic variation of the HIV-1 envelope protein in vivo, the molecular mechanisms of its conformational changes and immune escape, and deeply explored the impact of key amino acid mutations on the conformational states and immunogenicity of the envelope protein, providing new solutions for vaccine design. Moreover, leveraging her research experience with envelope proteins, she developed strategies for non-neutralizing antibodies to interfere with viral particle assembly, highlighting their potential use in gene therapy for AIDS​.

Since the emergence of SARS-CoV-2 in 2019, Qian has actively engaged in research related to this novel, emergent pathogen. Her primary focus revolved around characterizing the biochemical properties of the spike proteins of various SARS-CoV-2 variants, providing scientific guidance for pandemic control and preparedness. This systematic effort offered crucial data, illuminating the ability of Omicron subvariants to evade host immune pressure and increase receptor affinity. This knowledge has been instrumental in facilitating timely modifications to pandemic control strategies​. In addition, she evaluated antibody responses induced by COVID-19 mRNA vaccines to aid in the development and updating of vaccines.

Qian also assessed the neutralization capacity of clinical antibodies against emerging variants during the early stages of the pandemic, enabling adjustments in SARS-CoV-2 therapeutic interventions. An intricate analysis of mutations found in the spike proteins of different variants provided insights into their role in evading neutralizing epitopes and modulating receptor binding affinity. This molecular-level elucidation not only sheds light on the viral evolutionary trajectory, but also offers a scientific foundation for forecasting the spread of emergent variants​.